<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20521">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839746</url>
  </required_header>
  <id_info>
    <org_study_id>1160.253</org_study_id>
    <nct_id>NCT02839746</nct_id>
  </id_info>
  <brief_title>Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)</brief_title>
  <official_title>Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Describe patient and physician assessed factors for patient well-being when treated with
      Pradaxa for stroke and embolism prevention in atrial fibrillation either compared to
      previous antithrombotic treatment (switcher)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) scores at second and last assessment compared to baseline assessment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean of Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) score at last assessment compared to second assessment</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosing of Pradaxa</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender (male/famale)</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for atrial fibrillation stroke risk (CHA2-DS2-VASc score)</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function: creatinine clearance</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of previous vitamin K antagonist (VKA) treatment</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age (years)</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for Major Bleeding risk (HAS-BLED score)</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of participants with concomitant diseases</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of participants with concomitant therapies</measure>
    <time_frame>At baseline, visit 1 month, visit 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1087</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <description>Patients switched from vitamin K antagonist (VKA) to dabigatran</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        spanish patients with a diagnosis of non-valvular atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Written informed consent prior to participation

          -  Female and male patients 18 years of age or older with a diagnosis of non-valvular
             atrial fibrillation.

          -  At least 6 months of continuous vitamin K antagonist (VKA) treatment for stroke
             prevention prior to baseline assessment.

          -  Patients switched to Pradaxa® according to Summary of Product Characteristics,
             therapeutic positioning report from Spanish competent authorities and visa from each
             autonomous community.

        Exclusion criteria:

          -  Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product
             Characteristics (SmPC)

          -  Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in
             non-valvular atrial fibrillation.

          -  Current participation in any clinical trial of a drug or device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>One or multiple investigational sites</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
